Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.32
Q's Cash to Debt is ranked higher than
51% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. Q: 0.32 )
Q' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 0.32

Equity to Asset -0.17
Q's Equity to Asset is ranked lower than
54% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. Q: -0.17 )
Q' s 10-Year Equity to Asset Range
Min: -0.55   Max: -0.17
Current: -0.17

-0.55
-0.17
Interest Coverage 3.74
Q's Interest Coverage is ranked lower than
52% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. Q: 3.74 )
Q' s 10-Year Interest Coverage Range
Min: 2.79   Max: 3.74
Current: 3.74

2.79
3.74
Z-Score: 3.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 10.29
Q's Operating margin (%) is ranked higher than
86% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. Q: 10.29 )
Q' s 10-Year Operating margin (%) Range
Min: 7.98   Max: 10.07
Current: 10.29

7.98
10.07
Net-margin (%) 6.28
Q's Net-margin (%) is ranked higher than
84% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. Q: 6.28 )
Q' s 10-Year Net-margin (%) Range
Min: 3.65   Max: 5.59
Current: 6.28

3.65
5.59
ROA (%) 11.32
Q's ROA (%) is ranked higher than
94% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. Q: 11.32 )
Q' s 10-Year ROA (%) Range
Min: 7.36   Max: 20.82
Current: 11.32

7.36
20.82
ROC (Joel Greenblatt) (%) 284.91
Q's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. Q: 284.91 )
Q' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 208.78   Max: 371.69
Current: 284.91

208.78
371.69
» Q's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

Q Guru Trades in Q4 2013

Jim Simons 192,900 sh (New)
Joel Greenblatt 4,324 sh (New)
Caxton Associates 53,369 sh (New)
Vanguard Health Care Fund 3,636,278 sh (+193.45%)
Steven Cohen 9,344 sh (+95.48%)
Ron Baron 251,929 sh (-22.89%)
» More
Q1 2014

Q Guru Trades in Q1 2014

Paul Tudor Jones 17,916 sh (New)
Joel Greenblatt 17,666 sh (+308.56%)
Steven Cohen 30,923 sh (+230.94%)
Jim Simons 451,300 sh (+133.96%)
Ron Baron 327,309 sh (+29.92%)
Vanguard Health Care Fund 4,686,278 sh (+28.88%)
Caxton Associates 5,000 sh (-90.63%)
» More
Q2 2014

Q Guru Trades in Q2 2014

Ron Baron 402,309 sh (+22.91%)
Vanguard Health Care Fund 5,636,278 sh (+20.27%)
Steven Cohen 11,300 sh (unchged)
Caxton Associates Sold Out
Jim Simons 433,100 sh (-4.03%)
Paul Tudor Jones 12,942 sh (-27.76%)
Joel Greenblatt 7,008 sh (-60.33%)
» More
Q3 2014

Q Guru Trades in Q3 2014

Joel Greenblatt 477,607 sh (+6715.17%)
Paul Tudor Jones 24,488 sh (+89.21%)
Ron Baron 402,749 sh (+0.11%)
Vanguard Health Care Fund 5,636,278 sh (unchged)
Steven Cohen Sold Out
Jim Simons 237,400 sh (-45.19%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 6715.17%0.26%$54.42 - $58.67 $ 57.964%477607
Vanguard Health Care Fund 2014-06-30 Add 20.27%0.13%$46.75 - $53.33 $ 57.9615%5636278
Ron Baron 2014-06-30 Add 22.91%0.02%$46.75 - $53.33 $ 57.9615%402309
Joel Greenblatt 2014-06-30 Reduce -60.33%0.01%$46.75 - $53.33 $ 57.9615%7008
Vanguard Health Care Fund 2014-03-31 Add 28.88%0.15%$45.8 - $54.94 $ 57.9616%4686278
Ron Baron 2014-03-31 Add 29.92%0.02%$45.8 - $54.94 $ 57.9615%327309
Joel Greenblatt 2014-03-31 Add 308.56%0.01%$45.8 - $54.94 $ 57.9615%17666
Vanguard Health Care Fund 2013-12-31 Add 193.45%0.34%$41.58 - $46.48 $ 57.9632%3636278
Ron Baron 2013-12-31 Reduce -22.89%0.02%$41.58 - $46.48 $ 57.9632%251929
Joel Greenblatt 2013-12-31 New Buy$41.58 - $46.48 $ 57.9632%4324
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Quintiles Transnational Holdings Inc

Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO
According to GuruFocus list of three-year lows; Teradata Corporation, Quintiles Transnational Holdings Inc., Grana y Montero SAA and EXCO Resources Inc. have all reached their three-year lows. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.50
Q's P/E(ttm) is ranked higher than
90% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. Q: 22.50 )
Q' s 10-Year P/E(ttm) Range
Min: 20.63   Max: 31.56
Current: 22.5

20.63
31.56
P/S 1.41
Q's P/S is ranked higher than
88% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. Q: 1.41 )
Q' s 10-Year P/S Range
Min: 1.02   Max: 1.45
Current: 1.41

1.02
1.45
PFCF 24.05
Q's PFCF is ranked higher than
91% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. Q: 24.05 )
Q' s 10-Year PFCF Range
Min: 18.77   Max: 35.38
Current: 24.05

18.77
35.38
EV-to-EBIT 15.73
Q's EV-to-EBIT is ranked higher than
89% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. Q: 15.73 )
Q' s 10-Year EV-to-EBIT Range
Min: 14.8   Max: 18.3
Current: 15.73

14.8
18.3
Current Ratio 1.36
Q's Current Ratio is ranked higher than
54% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. Q: 1.36 )
Q' s 10-Year Current Ratio Range
Min: 1.15   Max: 1.42
Current: 1.36

1.15
1.42
Quick Ratio 1.36
Q's Quick Ratio is ranked higher than
58% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. Q: 1.36 )
Q' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.42
Current: 1.36

1.15
1.42

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.12
Q's Price/Median PS Value is ranked higher than
78% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. Q: 1.12 )
Q' s 10-Year Price/Median PS Value Range
Min: 0.82   Max: 1.11
Current: 1.12

0.82
1.11
Earnings Yield (Greenblatt) 6.40
Q's Earnings Yield (Greenblatt) is ranked higher than
89% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. Q: 6.40 )
Q' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.5   Max: 6.8
Current: 6.4

5.5
6.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:QTS.Germany
Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. The Company is engaged in providing biopharmaceutical development services and commercial outsourcing services. The Company's services offerings, helps biopharmaceutical customers, as well as customers in the healthcare industry, to make decisions regarding drug development, commercialization and drug therapy choices. The Company offers services through two segments Product Development; and Integrated Healthcare Services. The Product Development segment provides services and expertise that allow biopharmaceutical companies to outsource the clinical development process from first-in-man trials to post-launch monitoring. Its service offering provides the support and functional expertise necessary at each stage of development, as well as the systems and analytical capabilities to help customers improve product development efficiency and effectiveness. It is comprised of clinical solutions and services and consulting. Clinical solutions and services provide services to develop biopharmaceutical products including project management and clinical monitoring functions for conducting multi-site trials; clinical trial support services that improve clinical trial decision-making, such as global laboratories, data management, bio-statistical, safety and pharmacovigilance, early clinical development trials and strategic planning and design services. Consulting provides strategy and management consulting services based on life science expertise and advanced analytics, as well as regulatory and compliance consulting services. The Integrated Healthcare Services segment provides the healthcare industry with both geographic presence and commercial capabilities. Its customized commercialization services are designed to accelerate the commercial success of biopharmaceutical and other health-related products. It provides services including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as a growing number of healthcare business services for the broader healthcare sector. Its service offerings include commercial services and other healthcare services. The Company faces competition from traditional CROs, the in-house R&D departments of biopharmaceutical companies, universities and teaching hospitals. Its competitors include; Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc., or inVentiv, INC Research, PRA International, United Drug plc, inVentiv, EPS Corporation and CMIC HOLDINGS Co., Ltd in Japan. In the United States, pharmaceutical, biological and medical device products are subject to extensive regulation by the FDA. Its integrated healthcare services are subject to numerous federal and state laws pertaining to promotional activities involving pharmaceutical products and medical device
» More Articles for Q

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 
Qwest to Webcast Third Quarter 2009 Earnings Conference Call Sep 03 2009 
Qwest Reports Second Quarter 2009 Results Jul 29 2009 
Qwest Reports Fourth Quarter and Full Year 2008 Results Feb 10 2009 
Qwest Communications Announces Tax Treatment for 2008 Dividends Jan 19 2009 

More From Other Websites
Lightning Round: Do not own this Nov 24 2014
Quintiles Named a Best Workplace in South Korea Nov 19 2014
Quintiles Named a Best Workplace in South Korea Nov 18 2014
Quintiles Named a Best Workplace in South Korea Nov 18 2014
QUINTILES TRANSNATIONAL HOLDINGS INC. Files SEC form 8-K, Entry into a Material Definitive... Nov 10 2014
Quintiles CEO to Present at the Credit Suisse 2014 Healthcare Conference Nov 07 2014
Quintiles CEO to Present at the Credit Suisse 2014 Healthcare Conference Nov 07 2014
QUINTILES TRANSNATIONAL HOLDINGS INC. Financials Nov 06 2014
Quintiles Transnational (Q) Stock Down After Company Launches Secondary Offering Nov 05 2014
Quintiles Announces Launch of Secondary Public Offering and Repurchase of Common Stock Nov 04 2014
Quintiles Announces Launch of Secondary Public Offering and Repurchase of Common Stock Nov 04 2014
Stocks Stay Positive; Quintiles, Vipshop Break Out Nov 03 2014
Merger Monday: Publicis buys Sapient Nov 03 2014
Q3 2014 Quintiles Transnational Holdings Inc Earnings Release - Before Market Open Oct 30 2014
Quintiles Reports 3rd Quarter 2014 Results Oct 30 2014
QUINTILES TRANSNATIONAL HOLDINGS INC. Files SEC form 8-K, Results of Operations and Financial... Oct 30 2014
Quintiles Reports 3rd Quarter 2014 Results Oct 30 2014
Encore Ranked in Top 10 of Modern Healthcare’s 100 Best Places to Work in Healthcare Oct 28 2014
Encore Ranked in Top 10 of Modern Healthcare’s 100 Best Places to Work in Healthcare Oct 28 2014
How to Treat Ebola; Trust Your Instincts: Jim Cramer's Best Blogs Oct 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK